AtriCure (NASDAQ: ATRC) reported Q4 EPS of ($0.36), in-line with the analyst estimate of ($0.36). Revenue for the quarter came in at $35.9 million versus the consensus estimate of $35.89 million.

“We are pleased to report strong 2015 results, positioning us well in 2016 as we continue to execute on delivering our portfolio of innovative solutions for atrial fibrillation to the market,” said Mike Carrel, President and Chief Executive Officer of AtriCure. “Fourth quarter performance was marked by continued robust growth from U.S. customers and the successful commercial integration of the nContact acquisition. In the year ahead, we plan to further extend our leadership position as we ramp up our clinical trials, launch several new products into the market, and expand treatment of atrial fibrillation to improve patient lives.”

For earnings history and earnings-related data on AtriCure (ATRC) click here.